Tolmar Australia Pty Ltd has been acquired by Mundipharma Pty Limited

February 2018 — Tolmar International Limited, the owner of Tolmar Australia Pty Limited, has sold the company to Mundipharma Pty Limited. Financial details have not been disclosed.

Tolmar Australia is the Australian subsidiary of Tolmar International Limited, a global pharmaceuticals group focused on the manufacturing and distribution of pharmaceutical products including uro-oncology products. Tolmar Australia held the exclusive distribution and marketing rights for Eligard in Australia and New Zealand, a leading PBS-reimbursed prostate cancer therapeutic.

Mundipharma is a global pharmaceutical company with a large presence in Australia. Mundipharma is a leader in the development and provision of medicines for pain including treatments for cancer care, ophthalmology, respiratory, hydration and first aid. In addition, it is a member of a global network of independent associated companies that are engaged in research, development, production and marketing of prescription medicines and consumer healthcare products. Mundipharma has global operations spanning Europe, Asia, New Zealand, Latin America, the Middle East and North Africa.

Tolmar International is a global pharmaceuticals group focused on urology and oncology products. Tolmar’s team of highly trained research scientists, chemists and engineers work to deliver treatments that advance patient care around the world.

Our role in the transaction

Oaklins' team in Australia advised the seller in this transaction and ran a competitive and confidential sale process, managing interest from a broad range of global pharmaceutical companies, resulting in a successful result for the client. This deal demonstrates the team's ability to source and execute cross-border transactions generating interest on a global scale. This deal highlights the appeal of the Australian pharmaceuticals sector to international buyers.